BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Introduction 4) Line 94. It would be useful to outline what the benefit/harm trade-off is with coronary revascularization 5) Line94/95 -This sentence is unclear -which decisions? Denial of treatment? Any denying what care to others -are we talking more generally about health care or specifically about the condition? 6) Have there been any previous economic evaluations comparing the two treatments? If there has been, these should be briefly mentioned, and if not, it needs to be stated clearly that this is the first evaluation.
Methods 7)
In the first part of the methods both the model time horizon and model time cycle need to be specified -all we are is that it is a long-term analysis. 8) Details of the modelled patient population are not given. What is the gender split? What is the average age or age range? I am assuming this is a cohort model rather than a simulation? All of this information is required to give the reader a clearer picture of the modelling. 9) Line 116 -at what point after the index NSTEMI event do patients enter the model? 10) Line 129 -more detail is required regarding the "average UK population characteristics" to work out 10 year CVD risk from QRISK2. How did this population compare to the population modelled here? Are they comparable? 11) Line 160-162 -how did the population in the Cochrane review (to work out RR of stroke) compare with the data from RITA-3 for MI? 12) Line 168-170 -Further detail on the costing would be helpful, and could be provided in a supplemental file. 13) Line 180 -reference 32 is duplicated. 14) Line 193-194. The paper states that most parameter estimates are not included as distributions, as standard errors were unavailable. Were there any other measures of uncertainty for variables (e.g. SD, 95% CIs, or raw data containing numerators and denominators) which could be used in some way to represent uncertainty? I'm very surprised there is no measure of variability at all from the RITA-3 trial. The lack of the use of distributions limits the utility of the PSA and the value of information analysis and I feel that a revision of this paper would need further consideration of representing the parameter estimates as distributions. 15) Table 1 -page 6. What parameter is "stable" (with a value of 220)? Also page 7, what parameter is post-MI (value 280)? 16) Line 199. It is stated that utility decrements due to negative treatment effects such as bleeding were not modelled explicitly. This is the first time bleeding has been mentioned in the paper and therefore this statement requires more information -for examplebleeding from what? The invasive interventions or the conservative management? 17) Line 211 -it would be useful to explicitly list the sensitivity analyses to be undertaken with a rationale for each one.
Results

18)
Due to the uncertainty in many of the model parameters (and due to the lack of distributions) it would have been informative to also have presented the sensitivity analyses in a tornado diagram. This would be particularly useful for the RRs for MI and stroke to show what the value would need to be for the invasive intervention to be cost-effective at £20k/QALY. 19) Value of information analysis -I am unclear how true EVPPI could be calculated for clinical effectiveness when these parameters were not entered as distributions. 20) Page 20 -there are two sets of headings for this table.
Discussion 21) Line 258 -there is comparison here with a previous economic evaluation -reference to this earlier (in the introduction) would be useful in setting the scene for the paper. 22) Line 282 -further detail on the validation (particularly external validation) would be informative, even if in a supplemental file. 23) Page 10 first paragraph. This part of the discussion states that data was not specific to the NSTEMI population. It would be helpful to point out where this is the case when describing model assumptions in the methods section rather than alluding to it the first time in the discussion. 24) My main concern with the paper (as stated earlier) is that most parameters were not included as distributions and I feel this seriously limits the usefulness of the PSA & VoI results and as stated in the discussion underestimates the uncertainty. Ideally I would prefer the authors to explore further how they may represent uncertainty for the most important parameters. Linked to this I feel there should be stronger justification for the need for a trial to convince those who may conduct this type of trial.
REVIEWER
James Stone University of Calgary Canada REVIEW RETURNED 29-Apr-2019
GENERAL COMMENTS
The reviewer provided a marked copy with comments. Please contact the publisher for full details.
VERSION 1 -AUTHOR RESPONSE
We thank the two reviewers for their helpful and detailed comments on our manuscript. Please find below our responses.
Reviewer's comment Changes made in response
Reviewer #1
1. Is there any clinical proof that NSTEMI is considered to be a less serious condition than STEMI? NSTEMI patients tend to be elderly with worse outcomes. Please rephrase or provide references.
We have provided a reference for STEMI being the most acute form of heart attack (nhs.uk) (line 77)
Changed "less serious" to "less obstructive" (line 78) 2. Invasive therapy results in better clinical outcomes only for higher risk patients (TIMI score >2). Please rephrase.
Thank you for this comment we have added "higher risk"(line 87) and clarified what we mean by higher risk in line 89 3. RITA-3 data are almost 20 years old, and as such may significantly over-estimate adverse outcomes in contemporary NSTEMI care. Please add this to your list of limitations.
We have added the following to the limitations in lines 323-326:
"A further potential bias against the invasive strategy may have arisen from the fact that the trial from which the effectiveness data were obtained was conducted nearly 20 years ago and may not represent current practice, and as such we may have overestimated the adverse outcomes in contemporary NSTEMI care" 4. Operation related mortality from PCI and CABG registries. What is the average age of this population? Does it apply to your population?
Thank you for this point. The average age of operative mortality is 66 years for CABG and 65 years for PCI. The proportion of people dying because of surgery is low (1.1%). We may have under-estimated the risks of operative mortality for the older population that we modelled. However, when we model at a much higher level (10%) the invasive strategy was dominated (reinforcing our main conclusions). We have clarified this limitation in a footnote to Table 1 .
5. RITA-3 trial has been widely criticised because the conservative arm was unreasonably conservative and therapies such as Dual Antiplatelet Therapy (DAPT) were rarely provided to the conservative patients. Thus, it can be easily argued that DAPT and not an early invasive strategy was the cause for the observed difference. You need a better reference population.
We have added a caveat about the RITA-3 trials in response to comment 3 above. More specifically, we note that a meta-analysis (Fox, 2010) combined data from a number of trials and found that there was a reduction in incidence of MI at five years (10% in invasive; 12.9% in conservative). These data are consistent with the findings of the RITA-3 trial, at least at 5 years follow-up.
6. Results. The invasive strategy was not cost-effective. The reviewer added: "and even much less so without the inflated benefits of the early invasive strategy in lower risk populations"
Thank you for highlighting this upward bias. We noted that our results might have been affected by such bias in our 'Limitations' section (lines 327-330).
7. Key inputs (specific to NSTEMI) were not available. "Is this not a fatal flaw?"
We understand your concern. However, we believe this is a limitation of the existing evidence base. The analysis has taken NSTEACS findings as being transferable to NSTEMI. If they are not directly transferable then they would most likely make the early strategy more cost-effective than we report.
8. "Except that you cannot be sure who were the NSTEMI patients. You would be far better to simply do an analysis of <75 vs >75".
As noted above, the analysis took the NSTEACS findings as being transferable NSTEMI. This is because the policy question we were seeking to answer was "To assess the cost-effectiveness of the early invasive strategy versus medical management in elderly patients with NSTEMI" which is not strictly related to age. The process of modelling highlights the limitations of the evidence base on which real patient treatment decisions are being made now. The sensitivity analysis illustrates the considerable uncertainty that exists and the need for welldesigned clinical trials (with embedded economic evaluations) to inform patient care.
Reviewer #2
9. It would be useful state that the analysis is from an NHS perspective Apologies we have rephrased this sentence (see lines 96-97) to read "Such decisions may not be best for patients and may be waste of scarce health care resources, if invasive therapy were shown to be cost-effective." This we think clarifies the point and makes a stronger justification for the need for the work reported in our paper.
14.
Have there been any previous economic evaluations comparing the two treatments? If there has been, these should be briefly mentioned, and if not, it needs to be stated clearly that this is the first evaluation.
Stated that this was the first evaluation for NSTEMI (line 99). In the discussion we note that there is a cost-effectiveness analysis for patients with NSTEACS (line 286) 15. In the first part of the methods both the model time horizon and model time cycle need to be specified -all we are is that it is a long-term analysis.
Specified that this is a long-term model (line 104); Added the cycle length (lines 105-106)
16. Details of the modelled patient population are not given. What is the gender split? What is the average age or age range? I am assuming this is a cohort model rather than a simulation? All of this information is required to give the reader a clearer picture of the modelling. 20. Further detail on the costing would be helpful, and could be provided in a supplemental file.
We have prepared an additional supplementary file S5 ('Model methods') providing the data. This will be made available upon request.
Line 180 -reference 32 is duplicated
The duplicate has been removed.
22. The paper states that most parameter estimates are not included as distributions, as standard errors were unavailable. Were there any other measures of uncertainty for variables (e.g. SD, 95% CIs, or raw data containing numerators and denominators) which could be used in some way to represent uncertainty? I'm very surprised there is no measure of variability at all from the RITA-3 trial. The lack of the use of distributions limits the utility of the PSA and the value of information analysis and I feel that a revision of this paper would need further consideration of representing the parameter estimates as distributions.
For the RITA-3 trial data suitable for constructing distributions was only available for the composite outcomes (MI or death). Thus, we were restricted in our ability to incorporate information into the probabilistic sensitivity analysis. Despite this limitation the value of information analysis still showed considerable value in further research on the clinical effectiveness of treatments. Had we been able to incorporate the uncertainty surrounding these events we anticipate that the EVPI and EVPPI be the same or greater would be greater. We have made this point in the discussion under limitations (lines 333-340).
Additionally, we attempted to identify any potential distributions for our PSA. These have been incorporated into the analyses. found and/or were able to calculate the estimates for four additional distributions:
1) Probability of recurrent MI (calculated a standard error from the confidence intervals reported) 2) Probability of fatal stroke (used raw numbers of events and total sample to calculate a Beta distribution) 3) Post-stroke utility (since these were EQ-5D utilities we assumed a standard deviation of 0.3. Using the sample size of 457 (from Kalra (2000) -a trial from which we mapped the stroke utilities), we derived a standard error of 0.0014. 4) Post-MI-post-stroke utility (as above) All these changes are highlighted in Table 1. 23. Table 1 -page 6. What parameter is "stable" (with a value of 220)? Also page 7, what parameter is post-MI (value 280)?
Apologies for the mistake. These estimates refer to costs. We have now moved them to the relevant section in Table 1. 24. It is stated that utility decrements due to negative treatment effects such as bleeding were not modelled explicitly. This is the first time bleeding has been mentioned in the paper and therefore this statement requires more information -for example -bleeding from what? The invasive interventions or the conservative management?
Added bleeding to the introduction (line 95) and this is explained in the supplementary file (S5) 25. Line 211 -it would be useful to explicitly list the sensitivity analyses to be undertaken with a rationale for each one.
This has been made available in the supplementary file (S5) 26. Due to the uncertainty in many of the model parameters (and due to the lack of distributions) it would have been informative to also have presented the sensitivity analyses in a tornado diagram. This would be particularly useful for the RRs for MI and stroke to show what the value would need to be for the invasive intervention to be cost-effective at £20k/QALY.
Thank you for the suggestion. We agree that more could have been done to explore the uncertainties. Thus, we have performed sensitivity analyses for all variables for which measures of uncertainty were not available (only excluding those which were populationbased estimates, e.g. background mortality).
We used low values of -25% and high values of +25% for all variables. As suggested, we presented the results in a Tornado diagram (see lines 222-225 for the methods; and lines 250-254 for the results as well as Figure 3 ).
Since clinical effectiveness variables presented the greatest uncertainty, we have additionally performed threshold analyses for the RR_stroke and p_MI, and also RR_MI (a variable used in the sensitivity analysis). In the threshold analysis we identified the value that at which a variable would need at the point when the intervention just becomes costeffective (assuming a value of £20,000 for society's willingness to pay for a QALY). For both threshold analyses the values that the p_MI, and RR_MI would need to take are implausible (0.01 and 0.40). We describe the methods for these sensitivity analyses in lines 226-228 and the results 256-260.
27. Page 20 -there are two sets of headings for this table Thank you. The additional set of headings has been removed.
28. There is comparison here with a previous economic evaluation -reference to this earlier (in the introduction) would be useful in setting the scene for the paper. The focus of EVPPI in this analysis was relative treatment effectiveness. In particular, estimating unbiased relative effectiveness is best achieved using a randomised controlled trial design, so this estimate helps us consider the value of conducting such a study. More specifically, the EVPPI is based on the uncertainty surrounding RR stroke which has wide ranging confidence intervals. This EVPPI is a lower bound of the likely value of removing uncertainty in clinical parameters. Had it been possible to incorporate distributions for the clinical effectiveness in terms of MI, then the EVPPI would be greater and this reinforce the findings of our study (see also response to referee 1 comment 7)
32. Ideally I would prefer the authors to explore further how they may represent uncertainty for the most important parameters. Linked to this I feel there should be stronger justification for the need for a trial to convince those who may conduct this type of trial Please see our responses to comments 21, 25 and 28.
VERSION 2 -REVIEW
REVIEWER
Sue Jowett
Health Economics Unit, University of Birmingham, UK REVIEW RETURNED 01-Aug-2019 GENERAL COMMENTS I am happy with the additions and changes made to the paper and the responses given. I recommend the paper is accepted although I have three (final) minor suggestions.
1. page 9, line 263-264. I think this line would read better if it stated "Assuming these technologies will be used for the next 20 years, the EVPI is £38.30 million". This also requires thst, in line 263, the abbreviation EVPI to be put after it is written in full.
2. page 9, line 277. The PSA results are presented in the discussion for the early invasive strategy for £30k/QALY, in the abstract (page 2) for £20k/QALY and but in the main results section the results are presented for conservative managmeent (for both 20k and 30k/QALY). Whilst health economists will understand the figures, it may be preferable to be consistent in the presentation of the PSA resuults to help the non-health economists! 3. Page 9, 278. This doesn't read quite right -should it be "the total value of information over 20 years is....." or the "total EVPI over 20 years is......", rather than "the value of information anlaysis over 20 years is...".
